The full twelve-week course of direct acting hepatitis C antiviral oral medicines are now available to all Australians for the subsidized price of a little over A$100.00, or even less for concession card holders. This will allow all patients with this disorder, irrespective of socioeconomic status, genotype of the virus or the presence of cirrhosis to be cured and thereby reduce the risk of cirrhosis and liver cancer. The goal is to eradicate this disease in Australia.
by Dr. Richard O. Day, DIA Fellow; DIA Global Forum Regional Editor: Australia/New Zealand; Professor of Clinical Pharmacology, St. Vincent’s Hospital, Australia